Immutep Ltd · ASX:IMM
Immutep — Emergence Conference - Brisbane / Sydney - February 2019
17 slides from Immutep's conference presentation, Feb 26, 2019
Slide 1: Emergence Conference - The global leader in developing LAG-3 therapeutics
Emergence Conference - Brisbane / Sydney - February 2019 (ASX: IMM, NASDAQ: IMMP) The global leader in developing LAG-3 therapeutics
Slide 2: Notice: Forward Looking Statements
The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slid
Slide 3: Company Snapshot
Company Snapshot Globally active biotechnology company with operations in Australia, Europe and U.S. Four LAG-3 related product candidates in development in immuno-oncology and autoimmune disease Committed partnerships with five of the world’s largest pharmaceutical companies - Merck (MSD), Pfizer/
Slide 4: LAG-3 Overview & Product Candidates
LAG-3 Overview & Product Candidates
Slide 5: Targeting LAG-3/MHC II May Lead to Multiple Therapeutics in Numerous Indications
IMMUNOSTIMULATION IMMUNOSUPPRESSION APC MHCII IMP321 LAG-3 T-Cell T-Cell IMP761 APC Activator Antagonistic mAb Agonistic mAb Immuno-oncology Combination Therapies Viral Infections Rheumatoid Arthritis IBD Multiple Sclerosis Depleting mAb LAG-3 Partnered with Partnered with Targeting LAG-3/MHC II May
Slide 6: Immutep Controlled Immunotherapy Pipeline
Notes * Actual timing of data readouts may differ from expected timing shown above. Information in pipeline chart current as at 12 February 2019. In combination with KEYTRUDA® (pembrolizumab) in non-small cell lung carcinoma (“NSCLC”) or head and neck carcinoma (“HNSCC”); clinical trial is currently
Slide 7: Out-Licensed Immunotherapy Pipeline
Chemo-IO-Small Molecule Combo: Triple Negative Breast Cancer Notes Clinical trials currently planned and not yet active (as depicted by diagonal striped lines). Proof of concept data in Ulcerative Colitis for GSK’781 expected in 2H 2020. Reflects completed Phase I study in healthy volunteers and pso
Slide 8: Lead Program Eftilagimod Alpha (IMP321)
Lead Program Eftilagimod Alpha (IMP321)
Slide 9: Opportunity for Eftilagimod Alpha
Eftilagimod Key Characteristics (based on current data): First-in-class MHCII agonist Good safety profile and encouraging efficacy data thus far Potential for use in various combination settings (e.g. IO, chemo, vaccines or in situ immunization) Estimated favorable (low) cost of goods based on curre
Slide 10: Efficacy: Metastatic Melanoma
Efficacy: Metastatic Melanoma Tumour progression Efti (IMP321) in Melanoma TACTI-mel (IO combination) – Single Case at 1 mg efti Patient progressing on pembrolizumab monotherapy At 1 yr all lesions disappeared à CR (confirmed) Patient without treatment and disease free à now lost to FU Preliminary d
Slide 11: LAG-3 Landscape
P is) Immutep LAG-3 Landscape
Slide 12: LAG-3 Therapeutic Landscape Overview
LAG-3 Therapeutic Landscape Overview Immutep is the leader in developing LAG-3 modulating therapeutics Sources: GlobalData, company websites, clinical trials.gov, and sec.gov Information as of January 3, 2019, includes planned and completed trials, includes trials where the company may not be the sp
Slide 13: Increasing Clinical Trials Targeting LAG-3
Increasing Clinical Trials Targeting LAG-3 Industry increasingly deploying resources to development of LAG-3 therapeutics Sources: GlobalData, company websites, clinical trials.gov, and sec.gov Information as of January 3, 2019 *2019 includes planned and completed trials, includes trials where the c
Slide 14: Outlook
P is) Immutep Outlook
Slide 15: Outlook: Potential News Flow and Milestones
Outlook Potential News Flow and Milestones TACTI-mel data from fourth patient cohort (30 mg dose at cycle 1) in 2019 TACTI-002 to commence, Phase II trial in collaboration with MSD: H1 2019 TACTI-002 first data in 2019 INSIGHT-004 to commence, IIT Phase I trial in collaboration with Pfizer and Merck
Slide 16: Investment Highlights
Investment Highlights The global leader in developing LAG-3 therapeutics for immuno-oncology and autoimmune diseases Deep expertise and IP in the LAG-3 immune control mechanism Broadest LAG-3 portfolio with four product candidates, three of which are in nine ongoing or planned clinical trials Multip
Slide 17: Thank you!
P is) Immutep Thank you!
Immutep — Emergence Conference - Brisbane / Sydney - February 2019 on 6ix